Melanocortins and methods of use thereof
AssigneeAequus Biopharma, Inc.
InventorsRonald BERENSON, Christopher H. CLEGG
Life of this patent
Estimating the term…
Abstract
In some aspects, the present disclosure provides compositions and methods for treating disease, e.g., inflammatory disease. Compositions herein comprise one or more polypeptide fragments of proopiomelanocortin or variants thereof. The one of more polypeptide fragments of proopiomelanocortin or variants thereof may be linked by a linker, e.g., a peptide linker, to form a fusion polypeptide.
Claims119
A composition comprising:
- a first polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof;
- and
- a second polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof,
- wherein at least one of the first polypeptide and the second polypeptide binds to a melanocortin receptor.
A method of treating a subject in need thereof, the method comprising administering to the subject a composition comprising:
- a first polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof;
- and
- a second polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof, wherein at least one of the first polypeptide and the second polypeptide binds to a melanocortin receptor.
A method of reducing inflammation in a subject, the method comprising administering to the subject a composition comprising:
- a first polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof;
- and
- a second polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof,
- thereby reducing inflammation in the subject.
A method of reducing inflammation in a subject, the method comprising administering a single therapeutically effective dose of a composition, the composition comprising:
- a first polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof;
- and
- a second polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof that provides a maximum plasma cortisol concentration following administration that is less than 6 times the basal level concentration.
A method of reducing inflammation in a human subject, the method comprising administering a single dose of at least 0.1 nanomoles per kilogram (kg) and not more than 300 nanomoles per kg of a composition, the composition comprising:
- a first polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof;
- and
- a second polypeptide comprising a fragment of a proopiomelanocortin or a variant thereof.
Dependencies are inferred from the claim text.